BACKGROUND: Non-Hodgkin lymphoma (NHL), the most common cancer of the lymphatic system, is of unknown etiology. The identification of etiologic factors in the onset of NHL is a key event that could facilitate the prevention and cure of this malignancy. Simian virus 40 (SV40) has been considered an oncogenic agent in the onset/progression of NHL. METHODS: In this study, an indirect enzyme-linked immunosorbent assay with 2 synthetic peptides that mimic SV40 antigens of viral capsid proteins 1 to 3 was employed to detect specific antibodies against SV40. Serum samples were taken from 2 distinct cohorts of NHL-affected patients (NHL1 [n 5 89] and NHL2 [n 5 61]) along with controls represented by oncologic patients affected by breast cancer (BC; n 5 78) and undifferentiated nasopharyngeal carcinoma (UNPC; n 5 64) and 3 different cohorts of healthy subjects (HSs; HS1 [n 5 130], HS2 [n 5 83], and HS3 [n 5 87]). RESULTS: Immunologic data indicated that in serum samples from NHL patients, antibodies against SV40 mimotopes were detectable with a prevalence of 40% in NHL1 patients and with a prevalence of 43% in NHL2 patients. In HSs of the same median age as NHL patients, the prevalence was 16% for the HS1 group (57 years) and 14% for the HS2 group (65 years). The difference was statistically significant (P <.0001 and P <.001). Interestingly, the difference between NHL1/NHL2 patients and BC patients (40%/43% vs 15%, P <.001) and between NHL1/NHL2 patients and UNPC patients (40%/43% vs 25%, P <.05) was significant. CON-CLUSIONS: Our data indicate a strong association between NHL and SV40 and thus a need for innovative therapeutic approaches for this hematologic malignancy.
INTRODUCTION
Non-Hodgkin lymphoma (NHL) is a hematological tumor of unknown etiology. Its incidence increased until the mid1990s, and then it tended to stabilize. 1 It has been suggested that chronic inflammatory conditions, persistent infections, and immune impairments are risk factors. These conditions may allow 1) chromosomal translocations, 2) epigenetic modifications, 3) genetic mutations (including inactivation of tumor-suppressor genes), 4) immune suppression, 5) dysregulation of cytokine networks, and 6) clonal expansion of malignant cells. 2 The identification of etiologic factors in the onset of NHL is a key event that could facilitate the prevention and cure of this hematologic malignancy. Indeed, NHL is the most frequent malignancy among lymphoproliferative disorders. NHL represents a group of different but related hematologic malignancies with a remarkable clinicopathologic heterogeneity. The World Health Organization has classified 61 NHL types, which differ in their molecular profiles, growth patterns, and treatments. 3 There are 2 NHL major groups arising from transformed B cells and T cells, and they account for 85% and 15%, respectively. 4 It has been proposed that viruses with oncogenic potential may stimulate, during the lymphomagenesis, either cell multiplication or an inflammatory process that modifies the microenvironment. 4 Simian virus 40 (SV40), a small DNA tumor virus, is tumorigenic in mice. Rodents inoculated intravenously with this oncogenic virus develop distinct lymphoproliferative disorders, including B-cell lymphomas, lymphocytic leukemia, and histiocytic lymphomas. [5] [6] [7] [8] Recent data suggest that SV40 is a human lymphotropic virus that infects B and T cells while transforming at the same time a fraction of these lymphocytes. 9, 10 The SV40 genome encodes for 2 oncogene products named the large T antigen (Tag) and the small t antigen (tag). These viral oncoproteins drive the transformation and cancerogenic process by binding the cellular p53 and retinoblastoma protein polypeptides and thus abrogating their tumor-suppressor functions. 7 Moreover, it has been reported that SV40 is able to methylate human genes, which inactivate tumor-suppressor genes, [11] [12] [13] and to activate genes encoding for growth factors and their receptors, such as insulin-like growth factor, hepatocyte growth factor, and vascular endothelial growth factor. [14] [15] [16] SV40 has been advocated as a putative tumorigenic agent in the onset/progression of NHL. Several investigations have detected, mainly by polymerase chain reaction methods, SV40 footprints in hematologic malignancies. [17] [18] [19] [20] However, other studies have failed to reveal its sequences in NHL.
21 SV40 sequences were also reported, at a low prevalence, in peripheral blood mononuclear cells of normal subjects and in isolated/purified B and T cells of blood donors. 22 In SV40-positive human specimens, the viral DNA load is detected with a low copy number, and this indicates that human cells are semipermissive for its replication. In vitro, different human cells are permissive and allow SV40 to multiply. They lyse and die upon infection. Human fibroblasts represent a typical example. 23 There are also semipermissive cells such as human B and T cells. These cells allow SV40 multiplication, lyse, and die. However, a fraction of these persistently SV40-infected cells become transformed/immortalized and produce a viral progeny at a low titer. 9, 10 Human mesothelial cells seem to be a third human cell type. Indeed, in normal mesothelial cells, SV40 establishes a persistent infection and releases viral progeny at a low titer without an evident cytopathic effect (CPE). 16, 24 In most cases, the presence of SV40 antibodies has been tested in humans via immunologic techniques with virus-like particles as antigens. However, the homology among polyomaviruses such as SV40, BK virus (BKV), and JC virus (JCV) has produced data often affected by cross-reactivity. [25] [26] [27] [28] [29] Recently, a specific and sensitive indirect enzyme-linked immunosorbent assay (ELISA) for testing SV40 antibodies has been published. [30] [31] [32] [33] [34] [35] [36] This serologic test employs mimotopes as synthetic peptides corresponding to epitopes of SV40 viral capsid proteins 1 to 3 (viral peptides [VPs] ). This ELISA allowed us to reveal serum antibodies against SV40 VP antigen in healthy subjects (HSs) of different ages, such as children, 32 adults, 30 and elderly subjects, 36 and in patients with different tumors (ie, malignant pleural mesothelioma, 31 glioblastoma multiforme, 34 and osteosarcoma 35 ). In these tumors, which were experimentally induced in rodents by SV40, viral sequences were detected mainly by polymerase chain reaction techniques by some teams, whereas other groups were unable to confirm the association. 7, 37, 38 These conflicting results prompted us to use this novel indirect ELISA with SV40-specific mimotopes. In this study, sera from 2 independent NHL cohorts and controls (ie, breast cancer [BC] patients, undifferentiated nasopharyngeal carcinoma [UNPC] patients, and HSs) were investigated for the presence of specific SV40 antibodies.
MATERIALS AND METHODS

Samples
A total of 592 serum samples were collected at different institutions from NHL1 (n 5 89), NHL2 (n 5 61), BC (n 5 78), and UNPC patients (n 5 64) and from a wide spectrum of HSs (n 5 300 [HS1, n 5 130; HS2, n 5 83; and HS3, n 5 87]; see Tables (1 and 4) ). All sera were taken from discarded samples for clinical laboratory analyses, anonymously collected, and coded with indications of age, sex, and pathology (if any). NHL sera were taken from white patients and were collected before therapies. Written informed consent was obtained from patients and HSs. The project was approved by the county ethics committee of Ferrara, Italy.
Synthetic Peptides
Computer-assisted analyses allowed us to select SV40 peptides/epitopes of a late viral region through a comparison of Tag amino acids and 3 capsid proteins (VPs 1-3) from SV40 with the amino acids of the human BK and JC polyomaviruses (http://blast.ncbi.nlm.nih.gov). Two SV40 peptides belong to VP1/VP3 capsid proteins. The amino acid sequences of the 2 B and C peptides are as follows:
The synthetic peptides were synthesized with standard procedures and were purchased from UFPeptides srl (Ferrara, Italy). 30 
Control Immune Sera
Hyperimmune sera against SV40 and BKV were obtained from rabbits inoculated with purified viral stocks. The serum against JCV was kindly provided by Dr. Major (National Institutes of Health, Bethesda, MD). The immune serum against anti-BKV was titered via the hemagglutination inhibition test with human erythrocytes from the O Rh1 group. Additional SV40-positive and SV40-negative human sera were taken from our collections. [30] [31] [32] [33] [34] [35] [36] Indirect ELISA
The indirect ELISA with SV40 VP mimotopes was set up and developed as described in detail elsewhere. [30] [31] [32] [33] [34] [35] [36] Briefly, this ELISA was composed of the following phases.
Peptide coating
Each well was coated with 5 lg of the selected peptide in 100 lL of a coating buffer at pH 9.6 (Candor Bioscience, Germany).
Blocking
A blocking solution with casein (200 lL/well; Candor Bioscience) was added, and it was then left at 37 C for 90 minutes.
Primary antibody
Wells with sera (100 lL) included positive controls (represented by immune rabbit serum containing anti-SV40 antibodies), negative controls (represented by anti-BKV and anti-JCV immune sera), SV40-positive and SV40-negative human sera, and human serum samples under analysis (diluted 1:20 in LowCross-Buffer [Candor Bioscience]).
Secondary antibody
The solution included a goat anti-human immunoglobulin G (IgG) heavy and light chain-specific peroxidase conjugate (Calbiochem-Merck, Germany) diluted 1:10,000 in LowCross-Buffer.
Optical density (OD) reading
Samples, treated with 100 lL of a 2,2 0 -azino-bis 3-ethylbenzthiazoline-6-sulfonic acid solution (SigmaAldrich, Milan), were read at the spectrophotometer (Multiskan EX; Thermo Electron Corporation, Finland) at a wavelength of 405 nm.
Cutoff
The cutoff was determined for each assay with an OD reading of 3 negative controls, added to the standard deviation, and multiplied 3 times (13 standard deviations). Sera were considered SV40 VP-positive when they reacted to both mimotopes B and C. The indirect ELISA were replicated 3 times without result variability.
Plaque Reduction Method
CV-1 cells, permissive to SV40, were used in the neutralization assay via the plaque reduction method, as published recently. 31, 34, 35 SV40-infected cells were inspected for the CPE appearance for 21 days.
Statistical Analysis
The prevalence of SV40-positive serum samples from oncologic patients was compared with the prevalence detected in healthy individuals. All data are expressed as (25) 17 (27) 16 (25) Abbreviations: BC, breast cancer; HS, healthy subject; NHL, non-Hodgkin lymphoma; UNPC, undifferentiated nasopharyngeal carcinoma; VP, viral peptide. Human sera were taken from NHL1 and NHL2 patients, HSs (HS1 and HS2), BC patients, and UNPC patients. The prevalence of simian virus 40 antibodies in NHL1 patients was statistically significantly higher than that detected in the HS1 group (P <.0001), BC patients (P <.001), and UNPC patients (P <.05). The prevalence of simian virus 40 antibodies in NHL2 patients was statistically significantly higher than that detected in the HS2 group (P <.001), BC patients (P <.001), and UNPC patients (P <.05). The statistical analysis was performed with a chi-square test. a Versus the HS1 group. b Versus the HS2 group.
percentages. To determine significance between 2 groups, the 2-sided chi-square test and Fisher's exact test were used. All computational analyses were performed with Prism 4.0 (GraphPad software). For all tests, P was considered to be statistically significant when it was less than .05. The serologic profile of serum antibody reactivity to SV40 mimotopes was statistically analyzed with an analysis of variance and the Newman-Keuls comparison test.
RESULTS
Detection of SV40 VP Antibodies in Sera From NHL-Affected Patients
IgG antibodies reacting with SV40 VP antigens were investigated in sera from NHL patients with an indirect ELISA with specific SV40 VP mimotopes/epitopes. The ELISA test was used to assay sera taken from 2 different cohorts of NHL-affected patients: NHL1 (median age, 57 years) and NHL2 (median age, 68 years; Table 1 ). Sera were assayed for reactivity to SV40 VP1 antigens with the synthetic B peptide. Samples from NHL1 and NHL2 patients, reacting with the B mimotope, reached prevalences of 40% and 44%, respectively. The same indirect ELISA was used to verify the presence of antibodies against SV40 VP2/3 antigens with the mimotope known as VP2/3 C. Sera from NHL1 and NHL2 patients reacted with the C peptide with a prevalence of 43%, which was similar to that reported for the B mimotope. Interestingly, sera that tested negative for the B peptide did not react with the C mimotope. Few sera that were found negative for the B peptide reacted with the C peptide and vice versa; the difference was not statistically significant (P > .05; Table 1 ). The SV40-unrelated human neuropeptide S (hNPS) was used as a negative control in these ELISA tests. 30 Indeed, hNPS did not react with the human serum samples under analysis. The OD readings ranged from 0.08 to 0.09; these values were similar to those for a serum sample found to be SV40-negative, as reported before. [30] [31] [32] [33] [34] [35] [36] The 2 indirect ELISAs using the 2 distinct VP B and C peptides gave overlapping results and thus confirmed the presence of anti-SV40 VP antibodies in human sera from patients affected by NHL (Table 1) . Human sera were taken from NHL1 patients and HSs (HS1). The prevalence of simian virus 40 antibodies in NHL1 patients was statistically significantly higher than that detected in the HS1 group (P <.0001). The statistical analysis was performed with a chi-square test. P <.0001.
In our investigation, only those samples found positive for both B and C mimotopes were considered SV40-positive.
When we considered SV40-positive sera for SV40 B and C peptides from both NHL cohorts (NHL1 [n 5 36] and NHL2 [n 5 26]), the serologic results suggested that the prevalence was 40% and 43%, respectively (Table 1) . No significant difference in SV40 prevalence was detected among NHL types (Tables 2 and 3 ). The control represented by the human peptide unrelated to SV40 gave negative data. Indeed, the OD value (<0.1) was consistent with the data obtained with SV40-negative serum samples. Serum samples that tested SV40-positive via the indirect ELISA had a general cutoff around a spectrophotometric OD value of 0.18. In this study and in previous investigations, 0.18 is the OD value that differentiated SV40-negative sera (OD < 0.18) from those found to be SV40-positive (OD > 0.18). Human sera used as SV40-positive controls were from previous analyses performed with another method (ie, the inhibition of SV40 infectivity in the permissive cell line CV-1). 32, 33 These SV40 hyperimmune sera with a high value (OD > 1.8) were BKV-and JCV-negative. This result indicated that crossreactivity with these highly homologous human polyomaviruses did not occur. In addition, serum samples found to be JCV-and BKV-hyperimmune, used as negative controls, showed a value (OD < 0.1) that overlapped data of SV40-negative sera analyzed earlier. 28, 29 Immunologic profiles of NHL1 and NHL2 sera that reacted to SV40 antigens are shown in Figure 1 .
IgG Antibodies Against SV40 Antigens in Sera From Normal Subjects
Human serum samples (n 5 300) from HSs (HS1 [n 5 130], HS2 [n 5 83], and HS3 [n 5 87]) were analyzed for antibodies against SV40 epitopes. For this purpose, the indirect ELISA using synthetic peptides as SV40 VP antigens was employed. Sera from the HS1 group with the same median age (57 years) as that of the NHL1 group and sera from the HS2 group of the similar median age (65 years) as that of the NHL2 group were tested for their reactivity to SV40 B and C peptides from capsid proteins (VPs 1-3) .
The IgG class of serum antibodies against SV40 VPs, present in the 2 different HS cohorts (HS1 and HS2), showed prevalences of 16% and 14%, respectively (Table 1 ). In this indirect ELISA, sera that tested positive for the SV40 C peptide were found to be positive for the SV40 B peptide, too. In contrast, samples found to be negative for the SV40 B peptide did not react with the SV40 C peptide. Samples found to be negative or positive for VP1 B but positive or negative for VP 2/3 C peptide were very few. The difference in the prevalence of SV40 antibodies between the NHL1 and HS1 groups and between the NHL2 and HS2 groups was statistically significant (P < .0001 and P < .001; Table 1 ).
Immunologic profiles of serum antibodies from the HS1 and HS2 groups that reacted with SV40 epitopes are shown in Figure 1 . Mean OD values for sera from the NHL1 group for the B peptide and the B and C peptides are lower than those for sera from the HS1 group. These Abbreviations: B-CLL, B-cell chronic lymphocytic leukemia; HS, healthy subject; NHL, non-Hodgkin lymphoma; VP, viral peptide. Human sera were taken from NHL2 patients and HSs (HS2). The prevalence of simian virus 40 antibodies in NHL2 patients was statistically significantly higher than that detected in the HS2 group. The statistical analysis was performed with a chi-square test. P <.001
differences are statistically significant (P < .01 and P < .001, respectively; Fig. 1A,C) .
Antibodies Reacting to SV40 VP Antigens in Samples From Patients With BC
Serum samples from patients with BC (n 5 78; median age, 42 years), used as controls of another oncologic cohort, were analyzed via an indirect ELISA with SV40 VP antigens. BC is a tumor that is considered not to be associated with SV40. Breast carcinoma sera reacted to SV40 VP B and C peptides with an overall prevalence of 15%. The prevalence of SV40 antibodies in the NHL1/ NHL2 and BC groups differed significantly (P < .001). A prevalence (18%) similar to that found in BC patients was detected in an additional control group of healthy female subjects (HS3; n 5 87; median age, 42 years; Tables 1 and 4 ). Serologic profiles of BC and HS3 serum antibody reactivity to SV40 mimotopes are shown in Figure 1 .
SV40 Antibodies in Sera From Patients With UNPC
To verify the association between NHL and SV40, another control was added to the analyses in this study. Sera from UNPC-affected patients (n 5 64; median age, 57 years) were introduced into our investigation. It is worth recalling that UNPC is a herpesvirus Epstein-Barr virus-associated neoplasm. UNPC sera reacted to SV40 VP B and C peptides with a prevalence of 25% (Tables 1  and 4 ). The difference in the prevalence of SV40 antibodies for the NHL1/NHL2 and UNPC groups was statistically significant (P < .05). The prevalence (16%) found in the control group HS1 did not differ statistically from that for the UNPC group (25% ; Tables 1 and 4) . Serologic profiles of UNPC serum antibody reactivity to SV40 VP antigens are shown in Figure 1 . , and UNPC patients (0.1748 6 0.022) was lower than that for sera from the HS1 group (0.2730 6 0.023, **P <.001). The mean OD for sera from NHL2 patients was not statistically significant from that for sera from the HS2 group. (B) The mean OD (6 SEM) for VP C was not statistically significant in all sera (P > 0.05).
(C) The mean OD (6 SEM) for VPs B and C in sera from NHL1 patients (0.1568 6 0.007) and BC patients (0.1518 6 0.007) was lower than that for HS1 sera (0.2157 6 0.014, *P <.01). The mean OD for sera from NHL2 patients was not statistically significant from that for sera from the HS2 group. BC indicates breast cancer; HS, healthy subject; NHL, non-Hodgkin lymphoma; OD, optical density; SEM, standard error of the mean; UNPC, undifferentiated nasopharyngeal carcinoma; VP, viral peptide.
Inhibition of SV40 Infectivity
NHL and HS immune sera were assayed for their ability to neutralize SV40 infectivity. Ten SV40-positive immune samples that were diluted 1:20 (5 NHL samples and 5 HS samples with high ODs [ranges, 0.350-0.500 and 0.900-1.800]) were challenged in SV40-infected CV-1 cells for their ability to inhibit the SV40 CPE. 31, 34, 35 These SV40-positive sera were selected, among other samples, because they were BKV-and JCV-negative. 31, 34, 35 SV40 infectivity/CPE was not complete when SV40 immune sera with an OD of 0.350 to 0.500 (grades 1 and 2) were added to the infected cells. CPE was abolished with serum samples with an OD of 0.900 to 1.800 (grades 3 and 4), and this indicated that SV40 immune sera contained neutralizing antibodies. 31, 34, 35 We reason that these NHL patients and HSs carry neutralizing antibodies specifically elicited by SV40.
DISCUSSION
In this study, sera from 2 cohorts of NHL patients, labeled NHL1 (n 5 89) and NHL2 (n 5 61), and sera from 2 cohorts of HSs (HS1 [n 5 130] and HS2 [n 5 83]) with the same/similar median ages (57 and 65 years, respectively) as those of the NHL patients were analyzed via an indirect ELISA for their reactivity to SV40 VPs. The data indicated that the overall prevalence of the IgG class of SV40 antibodies in serum samples from NHL1 and NHL2 patients was 40% and 43%, respectively, whereas in their correspondent controls, HS1 and HS2, the prevalence was 16% and 14%. This difference was statistically significant (P < .0001 and P < .001). Because the association between 1 NHL cohort and SV40 could be due to chance, in our study, 2 independent NHL cohorts were analyzed. Our investigation gave statistically significant data for both NHL cohorts. These results strengthened the association between NHL and SV40.
To verify the prevalence of SV40 antibodies in another oncologic cohort used as a control, we investigated serum samples from BC patients (n 5 78). The rate of SV40 positivity among BC samples was 15%, which was not statistically different from the prevalence detected in the HS3 group (18%) with the same median age (42 years) 33 ; however, the difference between the 2 distinct cohorts of NHL-affected patients (NHL1 and NHL2) and the BC patients was significant (40% and 43% vs 15%, P < .001 and P < .001).
The prevalence of SV40 antibodies was investigated in an additional oncologic cohort. Sera from UNPC patients (n 5 64) were investigated. The rate of SV40 positivity among UNPC samples was 25%, which was not statistically different from the prevalence detected in the HS cohort (16%) with the same median age (57 years); however, the difference between the 2 distinct cohorts of NHL-affected patients (NHL1 and NHL2) and the UNPC patients was significant (40% and 43% vs 25%, P < .05 and P < .05).
These immunologic data indicate an association between NHL and SV40, whereas no association was shown between 1) BC and SV40 and 2) UNPC and SV40. It worth noting that a recent study, performed with sera from pregnant women analyzed by our indirect ELISA and the inhibition of SV40 infectivity, gave a similar prevalence of SV40 antibodies in 2 cohorts in the United States and Italy. 39 The genesis of NHL is unknown, but specific chromosome aberrations and gene mutations are detected in this commune lymphoproliferative disorder. Factors responsible for mutations/chromosome alterations are poorly understood. As for other cancers, chemical and physical agents together with oncogenic viruses may play a role in the onset/progression of this hematologic malignancy. SV40 is a small DNA tumor virus; its sequences have been detected mainly by polymerase chain reaction techniques in NHL. This result suggests that the viral agent with oncogenic potential may participate, probably as a cofactor, in the genesis of NHL. 11, 13, [17] [18] [19] [20] It is also plausible that SV40, as a passenger virus, multiplies in NHL-transformed cells without participating in the onset/progression of this hematologic malignancy. The presence of SV40 antibodies, with a high prevalence, in serum samples from NHL patients is not proof of cause/effect in the genesis of this lymphoproliferative disorder. On the other hand, it is also possible that after infecting the host, SV40 may exert its oncogenicity. It is well established that tumor viruses are able to induce human cancers under peculiar conditions of the host, such as a phase of immune depression/suppression. If SV40 is oncogenic in humans, new therapeutic approaches may be used with antiviral compounds or innovative therapies. In the next investigation, SV40 sequences and Tag expression together with an analysis of serum antibodies against SV40 will be studied in the same NHL samples.
Different studies indicate that SV40 infection is not widespread in humans, whereas human polyomaviruses such as BKV and JCV seem to be ubiquitous. 29 Some epidemiologic data suggest that SV40 could spread through contact in the familial environment or schools. SV40 footprints have been detected in stool, urine, tonsil, and blood specimens from children and adults, and this suggests that different routes of transmission are responsible for SV40 infection. 38, 40, 41 In agreement with this result, specific antibodies against SV40 have been revealed by different methods in sera from normal children, adults, and elderly subjects. 30, 32, 36 The partial and complete inhibition of SV40 CPE by immune sera from NHL patients and HSs, respectively, indicates a correlation between the level of antibodies and the grade of SV40 inhibition. 31, 34, 35 It should be noted that the level of SV40 antibodies, in terms of OD readings, is lower in sera from NHL patients versus HSs. It is possible that the low amount of neutralizing antibodies is not protective against SV40-induced or associated NHL.
The results of this study seem to confirm data of earlier reports obtained from individuals administered SV40-contaminated vaccines by different routes. In these vaccinèes, SV40 was detected/isolated after several days/weeks in the stool or throat (depending on the oral or nasal spray administration of contaminated vaccines).
